Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Ocugen stock price, quote, forecast and news

OCGN
US67577C1053
A2PSZH

Price

1.23
Today +/-
-0.01
Today %
-0.81 %
P

Ocugen stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ocugen stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ocugen stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ocugen stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ocugen's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ocugen Stock Price History

DateOcugen Price
9/11/20241.23 undefined
9/10/20241.24 undefined
9/9/20241.25 undefined
9/6/20241.14 undefined
9/5/20241.18 undefined
9/4/20241.16 undefined
9/3/20241.21 undefined
8/30/20241.30 undefined
8/29/20241.27 undefined
8/28/20241.29 undefined
8/27/20241.33 undefined
8/26/20241.36 undefined
8/23/20241.30 undefined
8/22/20241.23 undefined
8/21/20241.29 undefined
8/20/20241.21 undefined
8/19/20241.29 undefined
8/16/20241.24 undefined
8/15/20241.31 undefined

Ocugen Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ocugen, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ocugen from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ocugen’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ocugen. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ocugen’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ocugen’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ocugen’s growth potential.

Ocugen Revenue, EBIT and net profit per share

DateOcugen RevenueOcugen EBITOcugen Net Income
2029e359.47 M undefined0 undefined161.49 M undefined
2028e139.93 M undefined-6.99 M undefined-5.87 M undefined
2027e86.82 M undefined-34.05 M undefined-32.3 M undefined
2026e20.98 M undefined-79.81 M undefined-44.04 M undefined
2025e0 undefined-83.32 M undefined-71.94 M undefined
2024e3.01 M undefined-61.06 M undefined-57.26 M undefined
20236.04 M undefined-65.53 M undefined-63.08 M undefined
20220 undefined-84.87 M undefined-81.35 M undefined
20210 undefined-58.03 M undefined-58.37 M undefined
202040,000 undefined-21.28 M undefined-34.37 M undefined
20190 undefined-14.16 M undefined-20.24 M undefined
20180 undefined-25.84 M undefined-8.52 M undefined
20170 undefined-24.95 M undefined-22.5 M undefined
20160 undefined-30.11 M undefined-13.86 M undefined
20150 undefined-31.51 M undefined-32.02 M undefined
20140 undefined-32.6 M undefined-10.51 M undefined
201310,000 undefined-16.79 M undefined-56 M undefined
201230,000 undefined-14.97 M undefined2.81 M undefined
2011120,000 undefined-9.77 M undefined-24.82 M undefined

Ocugen Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000006302086139359
--------------50.00--330.0061.63158.27
-------------------
0000000000000000000
-9-14-16-32-31-30-24-25-14-21-58-84-65-61-83-79-34-60
-------------1,083.33-2,033.33--395.00-39.53-4.32-
-242-56-10-32-13-22-8-20-34-58-81-63-57-71-44-32-5161
--108.33-2,900.00-82.14220.00-59.3869.23-63.64150.0070.0070.5939.66-22.22-9.5224.56-38.03-27.27-84.38-3,320.00
0.180.180.180.210.220.240.380.6113.89112.24195.01214.6244.33000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ocugen Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ocugen is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
0.314.78.758.530.931.9815.57.4249590.939.46
0000000000000
0000000000000
0000000000000
0.80.31.60.80.30.20.20.98.31.87.77.63.51
1.11510.359.331.232.18.216.415.725.8102.798.542.97
2.92.32.34.95.23.92.70.10.21.12.81021.23
0000000000000
0000000000000
60060060050020000000000
0000000000000
0.831.60.80.10.10.10.90.80.40.40.20.34
4.35.94.56.25.542.8111.53.210.221.58
5.420.914.865.536.736.11117.416.727.3105.9108.764.55
                         
28.229.657.10.10.10.20.20.50.51.822.22.57
27.165.335.2187.6193.6195.2196.8215.96293.1225.5294.9324.19
-68.1-85-110.7-133.5-165.6-181.8-208.2-216.8-51.5-73.3-131.7-213-286.17
00000000000020
0000000000000
-12.89.9-18.454.228.113.6-11.2-0.41121.695.884.140.61
1.312.54.92.31.90.81.61.90.42.38.13.17
1.50.411.732.12.712.434.710.43.39
0.52.91.50.60.50.50.10.30.200010.53
0000000000000
00040060060020000200000
3.34.357.66.45.13.82.94.53.6718.517.09
12.7001.30.80.2001.11.81.72.32.8
20000700000000000
2.26.728.21.71.517.218.5150.20.41.23.84.09
15.16.728.23.72.317.418.5151.32.22.96.16.89
18.41133.211.38.722.522.317.95.85.89.924.623.98
5.620.914.865.536.836.111.117.516.827.4105.7108.764.59
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ocugen provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ocugen's financial health and stability.

Assets

Ocugen's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ocugen must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ocugen after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ocugen's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-12-16-25-22-32-16-26-8-20-21-58-81
00001,0001,0001,00000000
000000000000
-20120107-3-129
24812-114-13781422
000000000000
000000000000
-13-12-15-17-30-25-23-15-16-14-47-60
000-3-100-200-1-4
1,00000-3,000-1,0000-1,000-1,000-2,0000-1,000-16,000
1,0000000000-2,00000-12,000
000000000000
1260000001-400
0201070427025233712959
1126971427025253112059
----------1.00-8.00-
000000000000
014-549-270-24851670-17
-13.06-12.31-15.88-21.26-31.98-26.06-23.3-17.79-16.92-15.02-49.01-64.54
000000000000

Ocugen stock margins

The Ocugen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ocugen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ocugen.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ocugen's sales revenue. A higher gross margin percentage indicates that the Ocugen retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ocugen's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ocugen's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ocugen's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ocugen. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ocugen's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ocugen Margin History

Ocugen Gross marginOcugen Profit marginOcugen EBIT marginOcugen Profit margin
2029e0 %0 %44.92 %
2028e0 %-5 %-4.2 %
2027e0 %-39.22 %-37.2 %
2026e0 %-380.39 %-209.91 %
2025e0 %0 %0 %
2024e0 %-2,027.97 %-1,901.54 %
20230 %-1,085.67 %-1,045.03 %
20220 %0 %0 %
20210 %0 %0 %
20200 %-53,200 %-85,925 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %-167,900.01 %-560,000 %
20120 %-49,900 %9,366.67 %
20110 %-8,141.67 %-20,683.33 %

Ocugen Stock Sales Revenue, EBIT, Earnings per Share

The Ocugen earnings per share therefore indicates how much revenue Ocugen has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ocugen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ocugen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ocugen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ocugen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ocugen Revenue, EBIT and net profit per share

DateOcugen Sales per ShareOcugen EBIT per shareOcugen Earnings per Share
2029e1.25 undefined0 undefined0.56 undefined
2028e0.49 undefined0 undefined-0.02 undefined
2027e0.3 undefined0 undefined-0.11 undefined
2026e0.07 undefined0 undefined-0.15 undefined
2025e0 undefined0 undefined-0.25 undefined
2024e0.01 undefined0 undefined-0.2 undefined
20230.02 undefined-0.27 undefined-0.26 undefined
20220 undefined-0.4 undefined-0.38 undefined
20210 undefined-0.3 undefined-0.3 undefined
20200 undefined-0.19 undefined-0.31 undefined
20190 undefined-1.02 undefined-1.46 undefined
20180 undefined-42.36 undefined-13.97 undefined
20170 undefined-65.66 undefined-59.21 undefined
20160 undefined-125.46 undefined-57.75 undefined
20150 undefined-143.23 undefined-145.55 undefined
20140 undefined-155.24 undefined-50.05 undefined
20130.06 undefined-93.28 undefined-311.11 undefined
20120.17 undefined-83.17 undefined15.61 undefined
20110.67 undefined-54.28 undefined-137.89 undefined

Ocugen business model

Ocugen Inc is a US-based biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and vaccines. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. It has a strong pipeline of products in various stages of development, with a focus on treating eye diseases and other medical conditions. Ocugen has also entered into partnerships for the development and marketing of COVID-19 vaccines, including Covaxin. Overall, Ocugen Inc is expected to be a significant player in the biopharmaceutical industry in the coming years. Ocugen is one of the most popular companies on Eulerpool.com.

Ocugen SWOT Analysis

Strengths

1. Innovative Technology: Ocugen Inc has developed an innovative technology platform that focuses on novel biologics for treating various diseases.

2. Strategic Partnerships: The company has established strategic partnerships with leading pharmaceutical companies, enabling access to resources, expertise, and global distribution networks.

3. Strong R&D Capabilities: Ocugen Inc possesses strong research and development capabilities, allowing them to constantly innovate and develop new therapeutic solutions.

Weaknesses

1. Limited Product Portfolio: Currently, Ocugen Inc has a limited product portfolio, with only a few candidates in advanced stages of development.

2. Reliance on Partnerships: The company heavily relies on strategic partnerships for funding, manufacturing, and commercialization. This reliance may limit their independence and control over key aspects of the business.

3. Regulatory Challenges: The biopharmaceutical industry is subject to strict regulations, and any delays or failures in obtaining regulatory approvals could impact Ocugen Inc's ability to bring its products to market.

Opportunities

1. Market Expansion: Ocugen Inc can explore untapped markets and expand its reach geographically to maximize its revenue potential.

2. Growing Demand: The global demand for innovative biologics is increasing, providing an opportunity for Ocugen Inc to capture a larger market share.

3. Collaborative Research: Collaboration with academic institutions, research organizations, and other industry players can provide avenues for knowledge-sharing, resource pooling, and expanding the company's research capabilities.

Threats

1. Intense Competition: The biopharmaceutical industry is highly competitive, with numerous established players and new entrants. Ocugen Inc may face challenges in differentiating itself and capturing market share.

2. Economic Volatility: The company's financial performance and growth prospects can be impacted by economic downturns, currency fluctuations, and other macroeconomic factors beyond their control.

3. Intellectual Property Risks: Protecting intellectual property rights is crucial for Ocugen Inc. Any unauthorized use or infringements could undermine their competitive position and lead to revenue losses.

Ocugen Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ocugen historical P/E ratio, EBIT, and P/S ratio.

Ocugen shares outstanding

The number of shares was Ocugen in 2023 — This indicates how many shares 244.327 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ocugen earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ocugen's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ocugen’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ocugen's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ocugen Stock splits

In Ocugen's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Ocugen.

Ocugen latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.05 -0.04  (26.47 %)2024 Q2
3/31/2024-0.06 -0.05  (22.6 %)2024 Q1
12/31/2023-0.07 -0.03  (54.75 %)2023 Q4
9/30/2023-0.07 -0.06  (15.97 %)2023 Q3
6/30/2023-0.07 -0.08  (-6.95 %)2023 Q2
3/31/2023-0.11 -0.07  (36.48 %)2023 Q1
12/31/2022-0.1 -0.1  (0 %)2022 Q4
9/30/2022-0.1 -0.1  (0.3 %)2022 Q3
6/30/2022-0.08 -0.09  (-16.13 %)2022 Q2
3/31/2022-0 -0.09  (-3,361.54 %)2022 Q1
1
2
3
4

Eulerpool ESG Scorecard© for the Ocugen stock

Eulerpool World ESG Rating (EESG©)

38/ 100

🌱 Environment

36

👫 Social

41

🏛️ Governance

38

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees45
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ocugen list of shareholders

%
Name
Stocks
Change
Date
4.18256 % The Vanguard Group, Inc.12,039,918114,36612/31/2023
1.27750 % BlackRock Institutional Trust Company, N.A.3,677,415012/31/2023
1.01784 % Geode Capital Management, L.L.C.2,929,94868,48512/31/2023
0.56506 % Luminus Management, L.L.C.1,626,583-1,096,07312/31/2023
0.39787 % KVM Holdings, L.L.C.1,145,29904/13/2023
0.33520 % Zhang (Junge)964,90404/13/2023
0.29036 % State Street Global Advisors (US)835,826-45,80012/31/2023
0.24494 % Kompella (Uday B.)705,09004/13/2023
0.17708 % Northern Trust Investments, Inc.509,74964,88312/31/2023
0.17441 % Group One Trading, L.P.502,051336,91812/31/2023
1
2
3
4
5
...
10

Ocugen Executives and Management Board

Dr. Shankar Musunuri59
Ocugen Chairman of the Board, Chief Executive Officer (since 2019)
Compensation 7.66 M
Dr. Marna Whittington75
Ocugen Independent Director
Compensation 649,562
Dr. Prabhavathi Fernandes74
Ocugen Independent Director
Compensation 357,595
Ms. Kirsten Castillo50
Ocugen Independent Director
Compensation 348,182
Dr. Ramesh Kumar67
Ocugen Independent Director
Compensation 347,279
1
2

Ocugen Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
CanSino Biologics H Stock
CanSino Biologics H
SupplierCustomer0,250,890,690,630,670,63
MEDINET Stock
MEDINET
SupplierCustomer0,100,13-0,350,680,56-0,36
Jubilant Pharmova Stock
Jubilant Pharmova
SupplierCustomer-0,04-0,16-0,070,740,720,36
1

Most common questions regarding Ocugen

What values and corporate philosophy does Ocugen represent?

Ocugen Inc represents values of innovation, collaboration, and excellence in the biopharmaceutical industry. The company is dedicated to addressing unmet medical needs and improving patient outcomes through the development and commercialization of novel therapies. Ocugen Inc is committed to prioritizing patients and ensuring the highest standards of quality and safety in their products. With a focus on research and development, the company strives to bring breakthrough treatments to market, aiming to transform the lives of patients worldwide. Ocugen Inc's corporate philosophy centers around a patient-centric approach, ethical conduct, and delivering value to shareholders.

In which countries and regions is Ocugen primarily present?

Ocugen Inc is primarily present in the United States, focusing on the development and commercialization of innovative gene therapies. The company's headquarters are located in Malvern, Pennsylvania. Ocugen Inc also has a strong presence in India, where it has a subsidiary called Ocugen India Pvt. Ltd. Through partnerships and collaborations, Ocugen Inc strives to expand its reach globally, with a mission to provide solutions for rare and underserved diseases worldwide.

What significant milestones has the company Ocugen achieved?

Ocugen Inc has achieved several significant milestones in its history. The company successfully secured a strategic collaboration with Bharat Biotech to co-develop COVAXIN, a potential COVID-19 vaccine, for the US market. Ocugen also submitted a Emergency Use Authorization (EUA) application to the US FDA for COVAXIN, which marks a major milestone in bringing a potential vaccine to the market. Additionally, Ocugen received orphan drug designation from the FDA for its gene therapy product candidate for the treatment of RHO mutation-associated retinal degenerative disease. These milestones demonstrate Ocugen's dedication to advancing innovative healthcare solutions and its potential for growth in the biopharmaceutical industry.

What is the history and background of the company Ocugen?

Ocugen Inc is a pharmaceutical company with a strong focus on developing and commercializing gene therapies to treat blindness diseases. Established in 2013, Ocugen has been dedicated to advancing innovative treatments for various ocular disorders. The company's proprietary modifier gene therapy platform has shown promising results in preclinical and early clinical trials. Ocugen also partners with biopharmaceutical companies to expedite the development and distribution of potential therapies. With a commitment to improving patients' vision and quality of life, Ocugen Inc continues to make strides in the field of ophthalmology research and development.

Who are the main competitors of Ocugen in the market?

The main competitors of Ocugen Inc in the market include companies like Pfizer Inc, Moderna Inc, Johnson & Johnson, and Novavax Inc.

In which industries is Ocugen primarily active?

Ocugen Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Ocugen?

The business model of Ocugen Inc is focused on developing and commercializing transformative therapies for rare and underserved diseases. With a particular emphasis on gene therapies, the company aims to address unmet medical needs and provide effective treatment options for patients worldwide. Ocugen Inc collaborates with strategic partners to develop innovative therapies, leveraging their expertise in gene therapy platforms and advanced formulation techniques. By harnessing the power of genetic engineering and biotechnology, the company strives to bring life-changing solutions to patients suffering from various ophthalmic and other genetic disorders.

What is the P/E ratio of Ocugen 2024?

The Ocugen P/E ratio is -5.25.

What is the P/S ratio of Ocugen 2024?

The Ocugen P/S ratio is 99.81.

What is the AlleAktien quality score of Ocugen?

The AlleAktien quality score for Ocugen is 6/10.

What is the revenue of Ocugen 2024?

The expected Ocugen revenue is 3.01 M USD.

How high is the profit of Ocugen 2024?

The expected Ocugen profit is -57.26 M USD.

What is the business model of Ocugen

Ocugen Inc is a biopharmaceutical company based in the USA that focuses on the development and commercialization of innovative therapeutics for eye diseases. Ocugen's business model is based on partnerships with leading companies in the pharmaceutical industry as well as the development of its own products. The company operates in various areas including the development of therapeutics for eye diseases, licensing of technologies, products, and patents, and conducting clinical trials. Ocugen offers a variety of products, such as OCU300 for glaucoma patients and OCU200 for patients with dry eye disease. The company also has other products in the pipeline, such as OCU400 for retinal degeneration and OCU450 for retinal pigment degeneration. Ocugen's business model is focused on the development and commercialization of innovative therapeutics for eye diseases through partnerships and the development of its own products. By continuously evolving and expanding its offerings, Ocugen is well-positioned to meet the increasing demand for effective therapeutics for eye diseases in the future.

What is the Ocugen dividend?

Ocugen pays a dividend of 0 USD distributed over payouts per year.

How often does Ocugen pay dividends?

The dividend cannot currently be calculated for Ocugen or the company does not pay out a dividend.

What is the Ocugen ISIN?

The ISIN of Ocugen is US67577C1053.

What is the Ocugen WKN?

The WKN of Ocugen is A2PSZH.

What is the Ocugen ticker?

The ticker of Ocugen is OCGN.

How much dividend does Ocugen pay?

Over the past 12 months, Ocugen paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ocugen is expected to pay a dividend of 0 USD.

What is the dividend yield of Ocugen?

The current dividend yield of Ocugen is .

When does Ocugen pay dividends?

Ocugen pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ocugen?

Ocugen paid dividends every year for the past 0 years.

What is the dividend of Ocugen?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ocugen located?

Ocugen is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ocugen kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ocugen from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Ocugen pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Ocugen in the year 2023?

In the year 2023, Ocugen distributed 0 USD as dividends.

In which currency does Ocugen pay out the dividend?

The dividends of Ocugen are distributed in USD.

All fundamentals about Ocugen

Our stock analysis for Ocugen Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ocugen Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.